echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The new drug "increasingly emerging" precision medicine for prostate cancer is expected to rise.

    The new drug "increasingly emerging" precision medicine for prostate cancer is expected to rise.

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pancake prostate cancer is one of the most common cancers in the world and the second leading cancer killer among men worldwide.
    Prostate cancer in the early stages of no significant symptoms, and growth is relatively slow, reaching the late stage will appear urine frequency, urination difficulties, urinary blood, urine pain and other symptoms, and may be transferred to other parts, the general patient was found to be late cancer.
    because most patients are older and some early tumors grow slowly, a number of factors need to be taken into account in treatment.
    treatment methods except surgical cut, drug treatment is often associated with the treatment, because of the poor surgical effect of some late-stage patients, drug treatment is more commonly used.
    recently, the results of the results of two new drugs, but also for the rise of precision medicine for prostate cancer has brought hope, together to see.
    's new PI3K/AKT inhibitor, ipatasertibIpatasertib, is an oral, highly specific research drug designed to target and bind to all three subtypes of AKT (i.e., protein kinase B), which block the PI3K/AKT signaling path, a key driver of the growth and proliferation of prostate cancer cells.
    IPATential150 is a randomized, double-blind Phase III clinical trial designed to evaluate the efficacy of the first-line treatment of ipatasertib and abitor (metastatic prostate cancer).
    1101 patients were randomly divided into two groups, one receiving ipasertib, Abitron, and Ponieson, and the other receiving placebo, abitron, and pernisson.
    results showed that in patients with PTEN loss, the mesoimaging PFS (rPFS) was 18.5 months in patients in the ipatasertib-abitron-pernisson group, significantly better than the 16.5-month period in the placebo-abitron-pernisson group.
    patients without PTEN deficiency, there was no significant rPFS extension from subgroup analysis.
    study showed that for patients with PTEN's lost mCRPC, ipatasertib and abitron and pernisson were effective in prolonging the patient's PFS.
    the new immunotherapy drug AMG160 -- or can surpass the traditional immuno-checkpoint inhibitors in recent years, immunotherapy has become one of the most popular areas of cancer research, fundamentally changing the treatment method, so that cancer treatment into a new era.
    , however, the immunotherapy represented by PD-1/PD-L1 has not really "emerged" in prostate cancer treatment.
    AMG160 is a new HLE-BiTE immunotherapy that directs T cells to kill tumor cells by binding to PSMA on tumor cells and CD3 on T cells.
    PSMA is a tumor-related antigen that is overexpressed on the surface of metastatic and hormone-refractable prostate cancer cells.
    phase I study of AMG160 for mCRPC therapy was presented at the just-held ESMO Conference to assess the drug's safety, toerability, pharmacological dynamics and anti-tumor activity.
    as of 11 May 2020, 32 patients had received ≥1 dose of AMG 160 monotherapy at a dose level of 6 doses (DL) and 16 patients had received treatment (6 or ≥6 months).
    found that the most common adverse event cytokine release syndrome (CRS), which manifests it as fever, elevated transaminase, and low blood pressure, occurred mainly in the 1-2 cycle, and that 6/22 (27%) patients had prostate-specific antigen (PSA) reactions, and the results showed that AMG 160 treatment mCRPC had initial efficacy.
    the study group were all mCPRC patients after the failure of multi-line therapy.
    for such patients, there is currently no clear drug that can prolong the patient's OS.
    results, the PSA response rate in the treatment group was 27%, significantly higher than the PSA response rate of PD1/PDL1.
    PSA response rate of traditional immuno-checkpoint inhibitors is about 10%-15%, which fully demonstrates that AMG160 has good clinical application prospects.
    in the future, the AMG160 may be used in several ways, perhaps as a single drug, or in combination with some of the classic treatment options available, further extending the patient's survival time.
    the immunotherapy of prostate cancer started early, but limited to the characteristics of prostate cancer itself, its follow-up development is greatly limited.
    in recent years, the rise of ICI drugs, the field of prostate cancer research seems rather deserted.
    recently, with the exploration of immuno combination therapy, especially advanced prostate cancer has a variety of treatment methods, combination therapy has more room for choice.
    early studies such as
    immuno-combined chemotherapy, immuno-combined new endocrine therapy, and immuno-combined PARP inhibitors have achieved good anti-tumor efficacy, and follow-up studies are being carried out in many centers around the world, bringing a new dawn to immunotherapy for prostate cancer.
    that with the researchers' continuous efforts, prostate cancer can also find its own development prospects in the tide of cancer immunotherapy.
    with the publication of the results of the iatasertib and AMG160 studies, more new possibilities have been opened up in the field of prostate cancer treatment and a glimmer of hope for many prostate cancer patients, especially those with mcCRPC.
    source: 1. Genentech's IPATential 150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints.2. AbirateroneAcetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.3. Development of a Second-Generation Antiandrogen for Trent of Advanced Prostate Cancer.4. Sipuleucel-T (Provenge) Injection First Immunotherapy Agent (Vaccine) For Hormone-Refractory Cancer Prostate.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.